This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income
(NYSE: ABBV) is a large drug company with a somewhat unusual portfolio of products, spanning immunology (Skyrizi and Rinvoq) to esthetics (Botox). However, for many investors, the big draw is going to be the dividend. With a currently high yield and strong cash flow, AbbVie could provide dividend lovers with reliable income for years to come.
The S 500 index has a paltry yield of 1.1% today. The average pharmaceutical company, using iShares U.S. Pharmaceuticals ETF as an industry proxy, yields 1.7%. AbbVie's dividend yield is now 2.9%.
Image source: Getty Images.
Source Fool.com
AbbVie Inc. Aktie
176,30 €
0,43 %
Die Community liebt AbbVie Inc.: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Ein positives, wenn auch nicht starkes, Potenzial für AbbVie Inc. mit einem Kursziel von 209 € im Vergleich zu 176.3 €.
